Cord Blood News Volume 5.49 | Dec 12 2013

Ex Vivo Expansion of Hematopoietic Stem- and Progenitor Cells from Cord Blood in Coculture with Mesenchymal Stroma Cells from Amnion, Chorion, Wharton’s Jelly, Amniotic Fluid, Cord Blood, and Bone Marrow
Scientists investigated whether bone marrow-derived (mesenchymal stroma cells) MSCs, which have to be obtained in an invasive procedure, introduce a further donor and increases the risk of transmissible infectious diseases for the patient can be replaced by MSCs from amnion, chorion, Wharton’s jelly, amniotic fluid, and cord blood (CB), which can be isolated from placental tissue which is readily available when CB is sampled. [Tissue Eng Part A] Abstract

A Novel Reduced Intensity Conditioning Regimen for Unrelated Umbilical Cord Blood Transplantation in Children with Non-Malignant Diseases
Twenty-two children with a median age of 2.8 years, many with severe comorbidities and prior viral infections were enrolled in a novel reduced intensity conditioning protocol consisting of hydroxyurea, alemtuzumab, fludarabine, melphalan and thiotepa followed by single umbilical cord blood transplantation. [Biol Blood Marrow Transplant] Abstract

Role of FGF10 on Tumorigenesis by MS-K
The role of fibroblast growth factor-10 (fgf-10) on tumor growth was studied. MS-K enhanced more proliferation of endothelial cells by direct co-culture than NFSA, and rFGF10 supported the proliferation of HUVEC in combination with vascular endothelial growth factor-A. [Genes Cells] Abstract

A Preliminary Study on the Construction of Double Suicide Gene Delivery Vectors by Mesenchymal Stem Cells and the In Vitro Inhibitory Effects on SKOV3 Cells
Researchers aimed to investigate the efficacy of using human umbilical cord blood-derived mesenchymal stem cells as gene delivery vectors in the treatment of ovarian cancer. [Oncol Rep] Abstract

Sox2 Suppression by miR-21 Governs Human Mesenchymal Stem Cell Properties
Investigators isolated two subpopulations of fetal mesenchymal stem cells from amniotic fluid known as spindle-shaped and round-shaped cells and characterized them on the basis of their phenotypes, pluripotency, proliferation rates, and differentiation potentials. [Stem Cell Transl Med] Abstract

Visit our reviews page to see a complete list of reviews in the cord blood research field.

From our sponsor: Free human hematopoietic progenitors wallchart. Request your copy.

UTHealth Researchers Study Stem Cell Treatments for Children with CP
A first-of-its-kind clinical trial studying two forms of stem cell treatments for children with cerebral palsy (CP) has begun at The University of Texas Health Science Center at Houston (UTHealth) Medical School. The double-blinded, placebo-controlled study’s purpose includes comparing the safety and effectiveness of banked cord blood to bone marrow stem cells. [The University of Texas Health Science Center at Houston] Press Release

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

Visit our events page to see a complete list of events in the cord blood community.

Clinical MD – Clinical Development Program for Oncology and Autoimmune Diseases (Immunomedics, Inc.)

Chief Medical Officer – Novel Therapeutics in Oncology and Autoimmune Disease (Immunomedics, Inc.)

Director – Clinical Immunogenetics Laboratory (Fred Hutchinson Cancer Research Center)

PhD Studentship – iNKT Cells to Prevent Graft versus Host Disease (University of Birmingham)

Postdoctoral Associate – Graft-vs.-Host Disease and Graft-vs.-Leukemia in Mouse Models (Yale University School of Medicine)

Clinical Researcher – Hematopoietic Stem Cell Transplant Program (Northwestern University- Feinberg School of Medicine)

Postdoctoral Research Fellows – Isolation of Stem Cells from Placenta and Amniotic Fluid (Wake Forest Institute for Regenerative Medicine)

Adult Stem Cell Transplant Physician (John Theurer Cancer Center)

Scientist – Particle Chemistry (STEMCELL Technologies Inc.)

Research Technologist – Human Pluripotent Stem Cell Products (STEMCELL Technologies Inc.)

Research Associate/Scientist – Antibodies Group (STEMCELL Technologies Inc.)

Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.